TOP > 外国特許検索 > MEDICINAL COMPOSITION FOR TREATING NECROPTOSIS-RELATED DISEASE AND METHOD FOR SCREENING ACTIVE INGREDIENT THEREOF

MEDICINAL COMPOSITION FOR TREATING NECROPTOSIS-RELATED DISEASE AND METHOD FOR SCREENING ACTIVE INGREDIENT THEREOF

外国特許コード F150008212
掲載日 2015年3月25日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP053263
国際公開番号 WO 2014126127
国際出願日 平成26年2月13日(2014.2.13)
国際公開日 平成26年8月21日(2014.8.21)
優先権データ
  • 特願2013-025522 (2013.2.13) JP
発明の名称 (英語) MEDICINAL COMPOSITION FOR TREATING NECROPTOSIS-RELATED DISEASE AND METHOD FOR SCREENING ACTIVE INGREDIENT THEREOF
発明の概要(英語) One purpose of the present invention is to analyze the onset mechanism of severe enanthema, skin erythema, body surface erosion, blister and excoriation and provide a medicinal composition for fundamentally treating these symptoms. Another purpose thereof is to provide a method for screening an active ingredient of the aforesaid medicinal composition. In order to achieve these purposes, the present invention provides: a medicinal composition for preventing or treating a formyl peptide receptor 1-induced necroptosis-related disease, said composition comprising, as an active ingredient, a substance capable of inhibiting necroptosis that is induced by the binding of formyl peptide receptor 1 to annexin A1; and a method for screening a substance capable of inhibiting necroptosis that is induced by the binding of formyl peptide receptor 1 to annexin A1.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is the drug eruption, rash and reaction refers to the drug, the drug eruption is all drugs that can cause. A risk to life such as eruption by severe eruption to severe eruption is referred to, in its most severe Stevens, Johnson syndrome (Stevens-Johnson Syndrome; hereinafter, sometimes referred to as SJS) and toxic epidermal necrosis disease (Toxic epidermal necrolysis; hereinafter, sometimes referred to as TEN) is, necrosis of epidermal cells of the extra-high and a wide range of, poor disease prognosis. In SJS, lips, ophthalmic mucous membrane, such as severe mucocutaneous vulvar rash in the transition of the mucosa and skin erythema seen, body sores, blisters, body surface area is 10% or less abrasion. SJS is, due to the drug and may be of such virus other than said to, many of which are caused by the drug. The transition from the SJS TEN is included in the sub-type, their symptoms are similar to the SJS SJS and more severe as a whole, body surface area of greater than or equal to 10% sores, blisters, abrasion is seen. In addition, also on the skin and mucous membranes as well as the appearance of symptoms, which may be a blindness, and the case-fatality rate 20-25% TEN (non-patent document 1) are.
Cause agents include SJS and TEN, cefdinir cephems of the antibiotic, anti-epileptic drug (for example, zonisamide, carbamazepine, and phenobarbital), or non-steroidal anti-inflammatory drugs and, in addition to these 1100 causes drug is said to be more than two.
SJS and TEN for treatment of, such as heat generation or rash when early symptoms was observed, the administration of pharmaceutical agents cause estimated it is most important to immediately stop the best treatment method is called. However, initial symptoms of SJS and TEN, rash eruption symptoms appear only similar to the normal, the case is not diagnosed with SJS and TEN, discontinuation of the drug is delayed, the symptoms can become severe. Then, after the stop of the cause of the administration of pharmaceutical agents is a method for the treatment, the systemic administration of the corticosteroid agent, plasma exchange therapy, administration of the immunoglobulin, and is a topical antibiotic preparation to the skin surface, topical corticosteroid formulation is used. However, and these symptomatic treatment methods, and treatment of the underlying TEN SJS is not.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
  • 発明者(英語)
  • ABE Riichiro
  • SAITO Nao
  • SHIMIZU Hiroshi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください

PAGE TOP

close
close
close
close
close
close